This is a Phase 3, randomized, double blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with gemcitabine plus nab-paclitaxel in the treatment of locally advanced, unresectable pancreatic cancer subjects. 

Pamrevlumab or placebo will be administered on days 1, 8, and 15 of Treatment cycle 1 and Day 1 and 15 of subsequent cycles via IV infusion. Nab-paclitaxel and Gemcitabine are administered on Days 1, 8, and 15 of each 28 day cycle via IV. Patients will then undergo surgery 4 weeks after last dose of treatment. 

(FGCL-3019-087, IRB 2020-0399)

IRB 2020-0038
A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types
IRB 2020-0815
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma-2 (001
Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!

Our phone-based research recruitment app has features updates and a new look! It is available to all UC Cancer Center members and outside colleagues to aid in patient recruitment into cancer and other research studies.

Have you ever wanted to discuss research participation with a patient, but didn’t have the necessary study information at your fingertips to do so? The UC Cancer Center has partnered with High Enroll, LLC, to provide a valuable tool to solve this problem. This new phone-based application is available for all UC and non-UC referring providers. The new app allows for the entire recruiting portfolio of UC Cancer Center studies to always be updated by the research team. For each study, a summary, inclusion and exclusion criteria, other pertinent study information, and a “one-touch” contact button for the primary research coordinator are included

It takes only seconds to get the new app. On your phone, simply go to Add the app to your home screen for quick and easy use.  Please delete all other prior versions of the app. 

If you have any questions, please research out to your UC Cancer Center research team or High Enroll members, Dr. Dylan Steen @ 908-208-6927, or Ginger Conway @859-992-5339,



Dylan and Ginger

Doctoral student works on biosensors for cancer detection

Yuqian Zhang, an electrical engineering doctoral graduate of the University of Cincinnati, has focused her research on establishing innovative lab-on-a-chip devices for the rapid and sensitive detection of biomarkers for early disease diagnosis and prognosis. She has established rapid, cost-effective, easily operated and sensitive impedance biosensors to detect different classes of cancer related biomarkers with high sensitivity and specificity.
Click Here to Visit the UC Newsroom
UC Optimize Your Well-Being: Integrative Health and cancer survivorship 

Saturday, Jan. 23, 2021  | 9:30am-12:30pm
Virtual only, but registration is required. 

For more details about the Symposium Series, and to register visit

For more information or questions, email, or call 513-558-2030.

View Flyer as PDF
Division of Hematology Oncology Grand Rounds Schedule
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
Questions?  Please call us at 513-584-7698, or email us!
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA